InvestSMART

PainChek Ltd (ASX:PCK)

ALERT: Price-sensitive ASX Announcement for PCK
Current share price for PCK : $0.115 0.015 (15%)+
Announcement
Release
6 Jul 2026 4:33PM
Price at Release
$0.100
Full Release
download
Summary
PainChek Ltd announced the immediate transition of its CEO and Managing Director, Philip Daffas, as part of a planned strategy to support the company's Financial Year 2027 objectives following the FDA De Novo clearance. This decision aims to expedite the company's expansion into the US market. During his tenure, Mr. Daffas was instrumental in evolving PainChek from Australian research to a global entity with FDA clearance, over 20 million clinical assessments, and contracts with more than 2,000 aged care facilities. Andy Hoggan, the current COO, has been appointed as the Interim CEO while the search for a new CEO is underway.
Key Points
  • Philip Daffas stepped down as CEO of PainChek Ltd effective immediately.
  • The transition is planned to align with Financial Year 2027 strategy after FDA De Novo clearance.
  • PainChek aims to accelerate development in the US market.
  • Philip Daffas was pivotal in achieving FDA clearance and expanding operations internationally.
  • Andy Hoggan, the current COO, is appointed as Interim CEO.
  • The search for a new permanent CEO is in progress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.